Cost-effectiveness analysis of beta-blockers vs endoscopic surveillance in patients with cirrhosis and small varices

Table 2 Model variables: Baseline values

Variables	Baseline assumption
	12 mo	24 mo	36 mo	48 mo
Strategy 1 group
Intolerance to nadolol	4.8%	2.9%	0.0%	2.5%
Death	0.0%	4.5%	12.3%	7.7%
Lost to follow-up	10.1%	7.5%	12.3%	23.1%
Esophageal hemorrhage	0.0%	0.0%	0.0%	0.0%
Variceal growth	2.8%	3.4%	7.0%	0.0%
Strategy 2 group:
Death	1.3%	0.0%	15.6%	14.3%
Lost to follow-up	6.4%	6.7%	11.1%	21.2%
Esophageal hemorrhage	1.3%	1.7%	0.0%	0.0%
Variceal growth	15.5%	18.2%	15.2%	16.7%